Asthma and Airway Inflammation
Chiesi Farmaceutici S.p.A. is active in clinical research for asthma, including uncontrolled asthma, mild to moderate asthma, and moderate to severe controlled asthma. Its studies also address asthma exacerbations, lung function, and symptom control in patients receiving inhaled maintenance therapy.
- Asthma control
- Inhaled corticosteroid and bronchodilator therapy
- Forced expiratory volume in 1 second (FEV1)
- Exacerbation prevention
The sponsor’s respiratory portfolio includes work on inhaled treatments for persistent airway disease and the optimization of combination inhaler approaches in patients with chronic respiratory symptoms.
Chronic Obstructive Pulmonary Disease and Chronic Bronchitis
Clinical trials funded by the sponsor also focus on chronic obstructive pulmonary disease (COPD), including chronic bronchitis and overlap presentations with asthma. Research activity centers on respiratory symptom burden, airway obstruction, and long-term disease management in adults with persistent airflow limitation.
- COPD symptom control
- Triple inhaled therapy
- Airflow limitation
- Chronic bronchitis
These studies reflect sustained interest in inhaled therapies for obstructive lung disease and in treatment strategies for patients with advanced respiratory impairment.
Rare Metabolic Disorders
Chiesi Farmaceutici S.p.A. supports research in rare diseases such as Fabry disease and partial lipodystrophy. Trial activity includes adult and paediatric populations affected by inherited metabolic disorders associated with enzyme deficiency, abnormal lipid handling, and multisystem involvement.
- Fabry disease
- α-galactosidase A deficiency
- Partial lipodystrophy
- Metabolic disease
The sponsor’s research in this area includes therapies directed at systemic manifestations of rare metabolic conditions, with attention to both adult and paediatric clinical needs.
Fibrotic Lung Disease and Bronchiectatic Disorders
The sponsor is also involved in studies of idiopathic pulmonary fibrosis, pulmonary fibrosis, and non-cystic fibrosis bronchiectasis. These programmes address progressive structural lung disease, impaired respiratory capacity, and chronic airway damage.
- Idiopathic pulmonary fibrosis (IPF)
- Pulmonary fibrosis
- Bronchiectasis
- Restrictive lung disease
Research in these therapeutic areas reflects interest in chronic pulmonary conditions with limited treatment options and significant impact on breathing capacity and quality of life.
Neonatal Neurology and Respiratory Safety
Additional clinical activity includes neonatal hypoxic-ischemic encephalopathy (HIE) and studies in healthy volunteers examining cardiovascular safety, electrocardiographic monitoring, and drug interaction profiles relevant to inhaled and intranasal therapies.
- Neonatal hypoxic-ischemic encephalopathy
- Cardiovascular safety
- Electrocardiography
- Healthy volunteer studies
These areas show engagement with both early-life neurological injury and the safety evaluation of therapies used in respiratory medicine.
